Amygdala Volume

Introduction

Background

The amygdala is a pair of almond-shaped structures located deep within the temporal lobes of the brain. It plays a crucial role in processing emotions, particularly fear, as well as in memory formation, decision-making, and social interactions. Variations in the size, or volume, of the amygdala can reflect differences in brain structure that may be associated with diverse cognitive and emotional functions. Advanced neuroimaging techniques, such as Magnetic Resonance Imaging (MRI), enable detailed measurements of brain regions like the amygdala, providing insights into its structural properties. ^[1]

Biological Basis

Amygdala volume, like other brain structures, is influenced by a combination of genetic and environmental factors. Genome-wide association studies (GWAS) are widely used to identify specific genetic variants, known as single nucleotide polymorphisms (SNPs), that are associated with quantitative traits such as brain volumes. ^[2] These studies analyze the additive dosage effects of SNPs on phenotypes, controlling for other variables like age, sex, and population stratification. ^[1] While specific genetic variants linked directly to amygdala volume are actively being researched, studies have identified associations between genetic variations and the volumes of other brain regions, including the caudate, hippocampus, and temporal lobe. ^[2] High-resolution structural MRI scans are processed using automated segmentation methods, such as FreeSurfer or FMRIB’s Integrated Registration and Segmentation Tool (FIRST), to accurately delineate and measure specific brain region volumes. ^[2]

Clinical Relevance

Variations in amygdala volume and its functional activation are areas of significant interest in neuropsychiatric research. For instance, amygdala activation during face-processing tasks has been investigated in youths with and without bipolar disorder, revealing associations with genetic variations, such as an SNP (rs6354) in the 5′ UTR of the serotonin transporter gene (SLC6A4). ^[3] Alterations in brain volumes, including those of the hippocampus and caudate, have also been observed in conditions such as major depression and Alzheimer's disease. ^[2] Factors like medication exposure can influence both brain morphology and functional signals, highlighting the complexity of interpreting these findings. ^[3]

Understanding the genetic and environmental factors that influence amygdala volume has broad social importance. Research in this area contributes to a better understanding of individual differences in emotional processing, stress responses, and social behavior. This knowledge could potentially aid in the early identification of individuals at risk for certain neuropsychiatric conditions, paving the way for more personalized therapeutic and preventative strategies. By elucidating the complex interplay between genes, brain structure, and mental health, these studies can also help reduce stigma associated with mental health disorders and inform public health initiatives aimed at promoting brain health.

Methodological and Statistical Challenges

Genome-wide association studies (GWAS) investigating amygdala volume and related neuroimaging phenotypes face inherent limitations, particularly concerning sample size. While cohorts may be relatively large for typical neuroimaging studies, they are often considered small for comprehensive GWAS, which require extensive participant numbers to reliably detect common genetic variants with subtle effects. ^[3] This constraint can lead to reduced statistical power, increasing the risk of false-negative findings and necessitating analyses in combined populations to maximize detection capabilities. ^[3] Consequently, individual studies or smaller samples may struggle to achieve genome-wide significance, underscoring the critical need for replication in larger, independent cohorts to validate initial associations and build a more complete understanding of genetic determinants. ^[3]

The sheer number of genetic variants examined in GWAS, especially when multiple related phenotypes (e.g., left versus right amygdala volume, or different activation contrasts) are analyzed, introduces a substantial multiple-testing problem. ^[3] Although studies employ rigorous statistical corrections like the False Discovery Rate (FDR) or stringent genome-wide significance thresholds (e.g., p < 5×10^-8) ^[4] some research designs utilize less conservative thresholds in initial discovery phases, identifying "interesting" single nucleotide polymorphisms (SNPs) for subsequent replication rather than definitive genome-wide associations. ^[1] Researchers also meticulously assess for potential statistical biases, such as population stratification, by analyzing quantile-quantile (QQ) plots and calculating genomic inflation factors (lambda), which, when close to 1, generally indicate that observed p-value distributions align with the null hypothesis, thus mitigating concerns of widespread inflation of test statistics. ^[5]

Phenotypic Definition and Measurement Heterogeneity

The interpretation of findings concerning amygdala volume is intrinsically limited by the intricate nature of the neuroimaging phenotype itself. Factors such as the specific anatomical definition of regions of interest, potential confounding effects of medication, presence of psychiatric comorbidities, and variability in task performance (for activation studies) can all influence the measured volume or activation patterns. ^[3] Furthermore, the volume of a specific brain region like the amygdala is not entirely independent of overall brain size; genetic influences on subregional volumes might, in part, reflect effects on global brain volume. ^[1] To account for this, studies commonly adjust for intracranial volume (ICV) or express regional volumes as a percentage of ICV, though the exact, potentially non-linear, relationship between regional and global brain size remains a complex consideration. ^[6]

Another significant limitation arises from variability in neuroimaging acquisition protocols and post-processing algorithms across different research sites and studies. While automated segmentation software (e.g., FSL's FIRST, FreeSurfer) are rigorously validated against manual tracings, subtle differences in these algorithms, scanner sequences, or image resolution can introduce heterogeneity into the phenotype measurements. ^[5] Although such methodological variations are more likely to reduce statistical power and increase the chance of false negatives rather than invalidating detected associations, they can contribute to increased noise and complicate direct comparisons or meta-analyses across diverse datasets. ^[5] Rigorous quality control checks and the inclusion of site-specific or scanner-specific covariates are essential strategies to mitigate these effects. ^[1]

Generalizability and Unraveling Biological Mechanisms

A notable limitation in the generalizability of findings from many large-scale genetic studies on brain volumes is their predominant focus on cohorts of European descent. ^[5] While some studies attempt to statistically correct for ancestry or population stratification using covariates derived from genetic data, the underlying genetic architecture, allele frequencies, and linkage disequilibrium patterns can differ substantially across diverse ancestral populations. ^[3] Consequently, findings from one population may not directly translate to others. Beyond genetic factors, environmental influences and complex gene-environment interactions are recognized as crucial determinants of brain structure and function; however, comprehensively capturing and modeling these intricate interactions within current GWAS designs remains a significant challenge, representing a key area of ongoing investigation. ^[1]

Finally, a fundamental limitation of GWAS is their capacity to identify statistical associations between genetic variants and phenotypes, rather than directly elucidating the underlying biological mechanisms. While a specific genomic region might show strong association with amygdala volume, the precise functional impact of the associated SNPs on gene expression, protein function, or downstream cellular pathways is not immediately apparent. ^[1] Gaining a deeper mechanistic understanding would necessitate integrating genetic association data with functional genomics, gene expression profiling, and protein studies, which are often not available within the same cohorts. ^[1] Therefore, bridging the gap from statistical genetic associations to actionable biological insights and clinical pathophysiology requires extensive follow-up research beyond the initial GWAS.

Variants

Genetic variations play a crucial role in shaping brain structure and function, including the volume of the amygdala, a key region involved in emotion processing, memory, and social cognition. Variants within genes such as SLC39A8 and BANK1, as well as regulatory regions between them, have been investigated for their potential influence on neurodevelopment and neuroinflammatory processes that can impact amygdala size. For example, single nucleotide polymorphisms (SNPs) like rs13107325, rs13135688, and rs63519 in SLC39A8, which encodes a zinc transporter essential for neuronal health and synaptic function, may alter zinc homeostasis in the brain, potentially affecting neuronal plasticity and development within the amygdala. Similarly, BANK1 variants such as rs17199964, rs13119516, and rs12511373 are associated with immune system regulation, and their impact on neuroinflammation could indirectly influence amygdala volume and its susceptibility to stress-related changes. ^[7] Intergenic variants, including rs13101632, rs181121136, rs75088572, rs151407, rs151410, and rs238449, located between BANK1 and SLC39A8, may act as regulatory elements, modulating the expression of these nearby genes and thereby contributing to individual differences in brain morphology and emotional resilience. ^[8]

Other genetic loci, including those involving PARP11-AS1 and MSRB3, also contribute to the complex genetic architecture underlying amygdala volume. PARP11-AS1 is a long non-coding RNA that can regulate gene expression, and variants like rs2578475, rs10774183, and rs1419859 may alter its regulatory capacity, influencing pathways critical for neuronal development and maintenance. MSRB3 encodes Methionine sulfoxide reductase B3, an enzyme involved in antioxidant defense and protein repair, particularly within mitochondria, making variants such as rs17178006, rs1370938, and rs769345070 relevant for cellular stress responses in brain regions like the amygdala. ^[9] Dysregulation of these protective mechanisms could lead to cellular vulnerability, impacting neuronal integrity and, consequently, the size and functionality of the amygdala, which is highly sensitive to oxidative stress and metabolic changes. These genetic influences are often subtle, contributing to a polygenic risk profile that underlies variations in brain structure and related behavioral traits. ^[10]

Further contributing to this intricate genetic landscape are variants associated with HRK and intergenic regions near RPL36P15, GMNC, and OSTN. The HRK gene, also known as Harbinger of apoptosis, plays a role in programmed cell death, a process critical during brain development and in response to cellular stress. Variants like rs146607495 and rs188402627 in HRK, or rs11068224, rs7315280, and rs7137149 in the HRK - RPL36P15 intergenic region, could affect neuronal survival and plasticity, thereby influencing amygdala development and its adult volume. ^[11] Similarly, intergenic variants such as rs13070564, rs113591830, and rs58531798 located between GMNC (involved in cell cycle regulation) and OSTN (a protein in the extracellular matrix important for tissue development), may modulate gene expression in ways that affect neurogenesis, neuronal migration, or synaptic pruning, all of which are fundamental processes shaping brain regions like the amygdala. These genetic variations, through their impact on cellular processes, can influence the structural integrity and emotional processing capabilities associated with amygdala volume. ^[12]

Finally, intergenic variants within the SLC39A8 - NFKB1 region, specifically rs13140486, rs230489, and rs13131500, represent another set of genetic factors potentially influencing amygdala volume. NFKB1 is a central regulator of immune and inflammatory responses, and it plays vital roles in synaptic plasticity, learning, and memory within the brain. Variations in regulatory regions near NFKB1 could impact its expression or activity, thereby affecting neuroinflammatory states or neuronal signaling pathways that are crucial for amygdala development and function. ^[13] Given the amygdala's role in processing threats and emotional stimuli, alterations in inflammatory pathways or zinc transport, mediated by these variants, could lead to subtle but significant changes in its volume, influencing an individual's emotional reactivity and vulnerability to neuropsychiatric conditions. These intergenic variants highlight the importance of non-coding DNA in fine-tuning gene expression and ultimately contributing to complex brain phenotypes. ^[14]

Key Variants

RS ID	Gene	Related Traits
rs13107325 rs13135688 rs63519	SLC39A8	body mass index diastolic blood pressure systolic blood pressure high density lipoprotein cholesterol measurement mean arterial pressure
rs17199964 rs13119516 rs12511373	BANK1	intelligence brain volume insomnia total cholesterol measurement, triglyceride measurement, low density lipoprotein cholesterol measurement, high density lipoprotein cholesterol measurement amygdala volume
rs2578475 rs10774183 rs1419859	PARP11-AS1	amygdala volume hippocampal CA1 volume dentate gyrus volume hippocampal CA3 volume hippocampal CA4 volume
rs13101632 rs181121136 rs75088572	BANK1 - SLC39A8	brain volume intelligence alcohol consumption quality amygdala volume attention deficit hyperactivity disorder, autism spectrum disorder, intelligence
rs151407 rs151410 rs238449	BANK1 - SLC39A8	amygdala volume
rs17178006 rs1370938 rs769345070	MSRB3	hippocampal volume cerebral cortex area attribute brain volume brain attribute appendicular lean mass
rs11068224 rs7315280 rs7137149	HRK - RPL36P15	brain volume amygdala volume
rs146607495 rs188402627	HRK	brain volume brain attribute, neuroimaging measurement brain volume, neuroimaging measurement neuroimaging measurement amygdala volume
rs13070564 rs113591830 rs58531798	GMNC - OSTN	amygdala volume neuroimaging measurement
rs13140486 rs230489 rs13131500	SLC39A8 - NFKB1	amygdala volume osteoarthritis brain connectivity attribute cerebral cortex area attribute

Defining Amygdala Volume as a Quantitative Neuroanatomical Trait

Amygdala volume refers to the measured size of the amygdala, a critical subcortical deep gray matter structure involved in emotion processing, memory, and decision-making . This suggests that while some genes are critical for brain development and function, their direct impact on the static volume of specific structures like the amygdala may vary depending on the specific gene and population studied.

Environmental and Medical Modulators

External factors, including therapeutic interventions, can exert an influence on brain morphology. For example, certain medications, such as the mood stabilizer lithium, have been observed to induce both morphologic and functional changes within the brain. These alterations can affect the signals measured by fMRI, suggesting that such pharmacological exposures may contribute to variations in amygdala activity and potentially its underlying structure. ^[3] These medication-induced changes highlight the dynamic nature of brain structures and their susceptibility to environmental and pharmacological influences.

Developmental and Clinical Context

The volume of brain structures, including the amygdala, is subject to developmental trajectories and age-related changes across the lifespan. Factors such as age, sex, and their interactions are commonly recognized as significant influences on brain volumes, necessitating their consideration as covariates in neuroimaging studies. ^[1] These demographic variables contribute to the natural variability observed in amygdala volume within the population. Furthermore, certain neuropsychiatric conditions are associated with altered amygdala function, which may imply underlying structural or neurobiological differences. For instance, youths with bipolar disorder often exhibit amygdala hyperactivity, a phenomenon linked to deficits in face-emotion processing. ^[3] Unaffected youths who are at risk for bipolar disorder also demonstrate these face-emotion processing deficits, suggesting a familial association with the disorder. ^[3] While these findings primarily describe functional changes, they underscore the amygdala's central role in the neurobiology of mood disorders and its potential susceptibility to disease-related influences.

Amygdala Structure and Function

The amygdala is a vital subcortical structure located within the temporal lobe, integral to the brain's limbic system. ^[15] As a deep gray matter volumetric structure, its precise boundaries are defined by surrounding regions such as the putamen inferiorly, basal ganglia superiorly, the uncus medially, and the temporal lobe's white matter laterally . Docking proteins like DOK5 serve as substrates for tyrosine kinases, initiating intracellular signaling cascades by recruiting and assembling specific signal transduction molecules. ^[3] Specifically, DOK5 functions as a substrate for tropomyosin-related kinase B/C receptors, integrating into neurotrophin-induced mitogen-activated protein kinase (MAPK) signaling pathways. ^[3] This intricate molecular interaction is crucial for orchestrating the growth, survival, and differentiation of neurons, thereby contributing to the ultimate morphology and volume of the amygdala.

Genetic Influences on Amygdala Architecture

Genetic variations can modulate the structural architecture of the amygdala by impacting developmental and regulatory pathways. Genes such as DOK5 contribute to amygdala structure through their integral roles in neurotrophin signaling and neuronal maturation. ^[3] Similarly, variations in the brain-derived neurotrophic factor (BDNF) gene have been shown to affect amygdala activity in response to emotional stimuli, suggesting a broader influence of neurotrophic factors on both function and underlying structure. ^[16] However, while genetic variations in the serotonin transporter gene are known to influence amygdala activation, studies indicate that serotonin transporter gene status does not predict amygdala volume. ^[17] This highlights a distinction between genetic factors influencing dynamic activity versus static structural dimensions within the amygdala.

Pharmacological interventions can induce significant morphologic changes in brain regions, potentially affecting amygdala volume. For instance, the mood stabilizer lithium has been observed to increase human brain grey matter. ^[18] These medication-induced alterations can influence fMRI signals and the magnitude of the blood oxygen level-dependent (BOLD) signal, indicating a direct link between pharmaceutical effects, structural changes, and functional responses in the brain, including the amygdala. ^[19] In the context of disease, specifically bipolar disorder, a clear relationship exists between amygdala structure and function in affected adolescents. ^[20] This suggests that disease-relevant mechanisms involve pathway dysregulation that manifests as both functional alterations and potential structural remodeling, warranting further investigation into compensatory mechanisms.

Systems-Level Integration in Emotional Processing Circuits

The molecular and genetic pathways converge to establish the amygdala's critical role in processing emotions and integrating into broader neural networks. Dysregulation within these pathways, as observed in conditions like bipolar disorder, can lead to altered amygdala activation patterns. ^[3] Such alterations contribute to significant clinical manifestations, including deficits in social cognition, impaired response flexibility, and difficulties in facial emotion labeling in pediatric bipolar disorder. ^[21] Furthermore, these pathway dysregulations can result in impaired neural connectivity within the face emotion processing circuit, which heavily involves the amygdala. ^[22] These interactions exemplify how molecular mechanisms hierarchically regulate complex network functions, leading to emergent properties crucial for emotional behavior and affected in neuropsychiatric disorders.

Amygdala Volume in Bipolar Disorder

Studies have explored amygdala volume as a potential structural biomarker in neuropsychiatric conditions, including bipolar disorder. Research indicated that while individuals with bipolar disorder showed reduced gray matter volume in the ventral prefrontal cortex, a similar reduction was notably absent in the amygdala. ^[23] This specific finding suggests that amygdala volume may not be a primary structural biomarker reflecting the pathology or progression of bipolar disorder, distinguishing it from other affected brain regions. Therefore, its utility in diagnostic assessments or monitoring strategies for this condition, based solely on volume, appears limited.

Genetic Influence on Amygdala Volume and Major Depression

The relationship between genetic factors, amygdala volume, and major depressive disorder has been a subject of investigation. One study examined whether the status of the serotonin transporter gene, known for its role in mood regulation, could predict amygdala volume in older persons with major depression. ^[17] The findings revealed no significant association, suggesting that this particular genetic variant does not directly manifest as measurable changes in amygdala volume within this patient population. This limits the potential for using amygdala volume as a biomarker for risk stratification or personalized treatment selection based on serotonin transporter gene status in major depression.

Frequently Asked Questions About Amygdala Volume

These questions address the most important and specific aspects of amygdala volume based on current genetic research.

1. Why do some people seem less stressed than me?

It's a complex mix! Your amygdala, a brain region crucial for processing emotions like fear, varies in volume and activity due to both genetic and environmental factors. These structural differences can contribute to how individuals uniquely experience and respond to stress.

2. Am I born with a tendency to be more emotional?

Yes, to some extent. Your emotional responses are influenced by brain structures like the amygdala, whose volume and function are shaped by a combination of your genes and life experiences. While specific genes for amygdala volume are still being identified, genetic variations are known to influence other brain regions involved in emotion.

3. Will my kids inherit my emotional sensitivity?

It's possible for them to inherit a predisposition. Brain structures involved in emotional processing, including the amygdala, are influenced by genetic factors that can be passed down. However, environmental factors and their unique life experiences will also play a significant role in shaping their emotional development.

4. Does taking medication change my brain's emotional parts?

Yes, it can. Research indicates that medication exposure can influence both the physical structure (morphology) and the functional signals of brain regions involved in emotion, like the amygdala. This highlights the complex interplay between treatments and brain health.

5. Can my daily habits really shape my emotional brain?

Yes, they can play a role. While genetics significantly influence the structure of brain regions like the amygdala, environmental factors, which include aspects of your daily life, also contribute. The exact impact of specific habits on amygdala volume is an active area of research.

6. Why do my siblings and I react so differently to things?

Even with shared genetics, individual differences in brain structure and function, including the amygdala, can lead to varied reactions. Each person has a unique combination of genetic variations and distinct environmental exposures throughout life, which together shape these differences.

7. Could my brain's structure explain my mood challenges?

Potentially, yes. Variations in the volume of brain regions, including the amygdala, are areas of significant interest in neuropsychiatric research. Alterations in other brain volumes, like the hippocampus, are observed in conditions such as major depression, suggesting a link between brain structure and mood.

8. Does my family background affect my brain's emotional risks?

Yes, your genetic background can influence your brain's structure and function. Studies analyzing genetic variants need to carefully account for population stratification, meaning genetic differences between ancestral groups can contribute to variations in brain volumes and associated risks.

9. Is there a way to check my emotional brain's structure?

Yes, advanced neuroimaging techniques like Magnetic Resonance Imaging (MRI) can measure your brain structures, including the amygdala. These scans are processed with specialized software to accurately determine the volume of specific brain regions.

The amygdala plays a crucial role in social interactions, and individual differences in its structure and function can influence social processing abilities. These variations are influenced by both your genetic makeup and your experiences, contributing to how easily you interpret social cues.

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Stein, J. L. et al. "Identification of common variants associated with human hippocampal and intracranial volumes." Nat Genet, vol. 44, no. 5, 2012, pp. 542-551.

[2] Stein, J. L. et al. "Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search." Mol Psychiatry, vol. 16, no. 5, 2011, pp. 567-576.

[3] Liu, X. et al. "A genome-wide association study of amygdala activation in youths with and without bipolar disorder." J Am Acad Child Adolesc Psychiatry, vol. 49, no. 3, 2010, pp. 263-274.

[4] Bis, J. C. et al. "Common variants at 12q14 and 12q24 are associated with hippocampal volume." Nature Genetics, 2012, PMID: 22504421.

[5] Ikram, M. A. et al. "Common variants at 6q22 and 17q21 are associated with intracranial volume." Nature Genetics, 2012, PMID: 22504418.

[6] Hibar, D. P. et al. "Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects." Brain Imaging and Behavior, 2012, PMID: 22903471.

[7] Johnson, R. et al. "Genetic Factors in Amygdala Volume: A Review of GWAS Findings." Neuroscience & Biobehavioral Reviews, vol. 120, 2021, pp. 1-15.

[8] Chen, L. et al. "Regulatory Genomic Regions and Their Impact on Brain Structure." Molecular Psychiatry, vol. 25, no. 7, 2020, pp. 1389-1402.

[9] Davis, P. et al. "Role of Antioxidant Genes in Brain Health and Structure." Journal of Neuroscience Research, vol. 99, no. 1, 2021, pp. 100-115.

[10] White, T. et al. "Polygenic Risk Scores for Neuroimaging Phenotypes." Biological Psychiatry, vol. 88, no. 5, 2020, pp. 389-398.

[11] Miller, K. et al. "Apoptosis-Related Genes and Their Impact on Brain Development." Developmental Neurobiology, vol. 81, no. 2, 2021, pp. 150-165.

[12] Thompson, P. et al. "Genetic Mapping of Brain Structure: Insights from Large-Scale Neuroimaging Studies." Neuron, vol. 107, no. 3, 2020, pp. 436-451.

[13] Kim, S. et al. "Inflammation and Brain Structure: Genetic Links to Amygdala." Brain, Behavior, and Immunity, vol. 98, 2021, pp. 1-10.

[14] Smith, J. et al. "Genetic Influences on Subcortical Brain Volumes: A Meta-Analysis." Nature Neuroscience, vol. 20, no. 10, 2017, pp. 1472-1482.

[15] Furney, S. J. et al. "Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease." Mol Psychiatry, vol. 16, no. 11, 2011, pp. 1140-1147.

[16] Montag, Christian, et al. "The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study." Neuropharmacology, vol. 54, no. 5, 2008, pp. 776–83.

[17] Hickie, I. B., et al. "Serotonin transporter gene status predicts caudate nucleus but not amygdala or hippocampal volumes in older persons with major depression." J Affect Disord, 2007, vol. 98, no. 1-2, pp. 137–142.

[18] Moore, G. J., et al. "Lithium-induced increase in human brain grey matter." Lancet, vol. 356, no. 9237, 2000, pp. 1241–42.

[19] Phillips, M. L., et al. "Medication effects in neuroimaging studies of bipolar disorder." Am J Psychiatry, vol. 165, no. 3, 2008, pp. 313–20.

[20] Kalmar, J. H., et al. "Relation between amygdala structure and function in adolescents with bipolar disorder." J Am Acad Child Adolesc Psychiatry, 2009, PMID: 19454919.

[21] Brotman, M. A., et al. "Facial emotion labeling deficits in children and adolescents at risk for bipolar disorder." Am J Psychiatry, 2008, vol. 165, no. 3, pp. 385–389.

[22] Rich, B. A., et al. "Neural connectivity in children with bipolar disorder: impairment in the face emotion processing circuit." J Child Psychol Psychiatry, 2008, PMID: 18181882.

[23] Almeida, J. R. C., et al. "Reduced Gray Matter Volume in Ventral Prefrontal Cortex but Not Amygdala in Bipolar Disorder: Significant Effects of Gender and Trait Anxiety." Psychiatry Research - Neuroimaging, vol. 171, no. 1, 2009, pp. 54-68.